Tuberculosis (TB) lesions are extremely complex and dynamic. Here, we review the multiple
types and fates of pulmonary lesions that form following infection by M ycobacterium …

Rifampicin was discovered in 1965 and remains one of the most important drugs in
tuberculosis treatment that is valued for its sterilizing activity and ability to shorten treatment …

Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …

Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on
pharmacokinetic, toxicity, and cost considerations. Available data in mice and humans …

Pretomanid is a nitroimidazole antimicrobial active against drug-resistant Mycobacterium
tuberculosis and approved in combination with bedaquiline and linezolid (BPaL) to treat …

Multiple drug discovery initiatives for tuberculosis are currently ongoing to identify and
develop new potent drugs with novel targets in order to shorten treatment duration. One of …

Background Shorter but effective tuberculosis treatment regimens would be of value to the
tuberculosis treatment community. High-dose rifampicin has been associated with more …

Model‐informed drug development (MIDD) has a long and rich history in infectious
diseases. This review describes foundational principles of translational anti‐infective …

Tuberculous meningitis (TB meningitis) is the most severe form of tuberculosis (TB),
requiring 12 months of multidrug treatment for cure, and is associated with high morbidity …

Although high-dose rifampicin holds promise for improving tuberculosis control by
potentially shortening treatment duration, these effects attributed to eradication of persistent …